2020
Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.
Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology Case Reports 2020, 3 PMID: 33778814, PMCID: PMC7993656.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyElective colectomyUlcerative colitisInhibitor therapyMetastatic melanomaImmune-related adverse eventsExcellent tumor responseImmune checkpoint inhibitorsSevere ulcerative colitisActive ulcerative colitisCheckpoint inhibitor immunotherapyCheckpoint inhibitor treatmentInflammatory bowel diseaseEffective treatment optionBenefits of treatmentImmune system activationTumor cell destructionCheckpoint inhibitorsAdvanced malignanciesAdverse eventsSelect patientsBowel diseaseAutoimmune diseasesTreatment optionsTumor response
1993
Pathological evaluation of the regional lymph nodes in malignant melanoma.
Robert M, Wen D, Cochran A. Pathological evaluation of the regional lymph nodes in malignant melanoma. Seminars In Diagnostic Pathology 1993, 10: 102-15. PMID: 8506413.Peer-Reviewed Original ResearchConceptsLymph node metastasisNode metastasisMalignant melanomaLymph nodesDevelopment of lymph node metastasesPrognostic significance of metastasisDiagnosis of metastatic melanomaClinical stage II diseaseSurvival rateFive-year survival rateStage I melanomaDetection of micrometastasesPathological risk factorsStage II diseaseRegional lymph nodesMetastatic melanomaII diseasePrognostic significancePathological evaluationDifferential diagnosisMelanomaRisk factorsMetastasisClinical implicationsLymph